Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,219 Mln
Revenue (TTM)
$389 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
36.1
P/B Ratio
5.9
Industry P/E
--
EV/EBITDA
38.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$40.7
EPS
$6.8
Face value
--
Shares outstanding
29,232,189
CFO
$-296.75 Mln
EBITDA
$-338.60 Mln
Net Profit
$-269.83 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 5.8 | -5.3 | 5.8 | 49.5 | 48.3 | 27.7 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 57.4 | 26.0 | 56.6 | 13.3 | 16.6 | 8.3 | 166.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
|
261.0 | 7,218.6 | 389.1 | 204.8 | 41.5 | 18.9 | 36.1 | 5.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK... (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203 Read more
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Headquarters
Pittsburgh, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Krystal Biotech Inc (KRYS) is $260.95 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Krystal Biotech Inc (KRYS) has given a return of 48.27% in the last 3 years.
The P/E ratio of Krystal Biotech Inc (KRYS) is 36.10 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
36.11
|
6.06
|
|
2024
|
52.71
|
4.97
|
|
2023
|
317.75
|
4.46
|
|
2022
|
-14.15
|
3.79
|
|
2021
|
-22.12
|
2.59
|
The 52-week high and low of Krystal Biotech Inc (KRYS) are Rs 298.30 and Rs 122.80 as of 03-Apr-2026.
Krystal Biotech Inc (KRYS) has a market capitalisation of $ 7,219 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Krystal Biotech Inc (KRYS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$2.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.